Inato secures $14m investment for clinical trial matching platform

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Champc)
(Image: Getty/Champc)

Related tags: Inato

The Series A financing round arrives as the company suggests it is able to reduce the number of sites needed by a clinical trial by 29%.

Inato, based in Paris, France, possesses a platform that matches a clinical trial site with a sponsor, but in a fashion that increases the pool of available patients, the company suggests.

As a result of the offering, Obvious Ventures and Cathay Innovation joined previous backers, in Serena and Fly Ventures, to fund Inato to the tune of $14m (€12.7m).

Despite being the company’s first significant financing round, it has already aided the operations of over 50 global clinical trials across 2,000 research sites.

“Five percent of the world’s research sites are conducting the vast majority of today’s clinical trials. When you consider that the average cost of bringing a drug to market is around $2 billion, with about two-thirds of those costs tied to clinical trials, it’s clear there’s an urgent need for greater efficiency,”​ said Inato Co-Founder and CEO Kourosh Davarpanah.

Davarpanah continued to suggest Inato will work to bring doctors, and their patients, into its clinical research ‘ecosystem’.

The company will use the funds raised to improve its platform’s predictive capabilities, in matching sites with clinical trials, and to develop a global network of clinicians. Currently, Inato states that the product’s algorithm can help reduce the number of sites needed in a study by 29%.

In addition to Obvious Ventures’ investment, its managing director, Nan Li, will also join Inato’s board of directors.

Related news

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars